The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Neither Harding or her husband seem to properly get the concept of meeting health need. Ots a national emergency ffs and all validated tests should be prioritised and allocated to settings and situations according to clinical, social and economic crtieria. And they should be bought and distributed out of the public purse at a level and in a fashion that will strongly drive down r. Leaving businesses to make and pay for their own choices is just daft. Its cheaper than the costs of mass unemployment benefit and lost business taxes.
Hi Captain - Batch testing has been used in places like Portugal and can be handy in the right contexts. School bubbles, family bubbles and workplace bubbles are all good examples. However, there are also many use cases where you need a quick individual test - events being one, sent home from school or work with a cough, getting on a plane etc....
So very much agree with Bella too. To really beat r down whilst keeping economy relatively open you need millions of individual rapid turn around tests and its seems high quality cheap self administered tests really are the Holy Grail to that end.
Timster - seems Abingdon and BBI have a lot of sites oberseas too and along with Cytiva can really help start to beat r down globally
I would say why don't you pop around his house and ask if you can feed directly on his twitter teat, but I suspect the restraining order would stop that.
Has Myles posted any new timelines as it's looking like Sept is nearly over and still no result from AVCT?
Note not nite..
'We therefore continue to actively seek additional manufacturing partners globally to be able to provide the volume of tests that will be required in the UK and elsewhere.'
Nite the word 'will'.. And why would any company go to the expense of lining up several manufacturing partners... Why not one and if they are successful then bring on more as you go...
No, the know they are going to need the capacity because they already have the feedback from potential customers. When they get the go ahead this will go big....
The key difference is the phrase 'mass' testing.
Lab testing can no longer cope in the UK due to lack of staff...mainly those drawn from universities. The current system is full of travel/transport so very inefficient.
I do feel the UK Govt has changed its emphasis and is talking about mass testing being two pronged... Existing in lab where applicable and on site/very localised using qualified technicians etc and in home tests which can be done by individuals directly be it yourself or care home staff etc....this is the area they are hinting at but not talking about in great detail because its not available yet due to lack of regulation and/or manufacturing/availability timescales not yet fully known.
I do feel they will not announce anything until they have it all ready to roll out and they can say test kits, are now being set to... Your doctor, care homes, schools etc.
Also believe any announcement will be tied in with a Government announcement. A rapid test such as ours is pivotal to their testing strategy. They will hail it as their great success.....
uses the same affimers as in the Avacta ELISA test:
Using the same Affimer reagents that are incorporated into its rapid coronavirus saliva test being developed with Cytiva, Avacta has developed in-house a high performance ELISA laboratory test to detect the SARS-CoV-2 virus. Avacta will make the ELISA test available as a kit so that researchers globally can use it in their own laboratories to support research into the coronavirus.
which is 500 times more sensitive than the competition:
https://avacta.com/alastair-smith-gives-more-detail-on-the-sars-cov-2-elisa-laboratory-test/
IT WORKS!!! the issue is manufacturing capacity:
Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the SARS-CoV-2 coronavirus. The test has the potential to be used for frequent mass testing of the population to promptly identify infectious individuals so that they can be isolated and treated, thereby reducing the spread of infection.
Abingdon Health provides innovative rapid testing solutions to a global client base and has Europe's largest lateral flow test contract manufacturing capacity. Abingdon Health's two sites in York and Doncaster, UK are able to produce millions of rapid tests per month.
Authorities around the world are now looking to carry-out frequent mass testing to identify the most infectious people promptly in order to reduce infection rates and combat the coronavirus pandemic. That requires a highly specific test to minimize false positives which would otherwise overwhelm healthcare systems. The Affimer reagents that we have generated are very specific to SARS-CoV-2 antigen and we are confident of meeting and exceeding the clinical performance requirements for identifying the most infectious people.
Manufacturing capacity is therefore the key challenge that has to be met in achieving widespread roll-out of Avacta's saliva-based rapid antigen test. We therefore continue to actively seek additional manufacturing partners globally to be able to provide the volume of tests that will be required in the UK and elsewhere. I look forward to updating the market on progress in that regard, and will keep the market informed on the key next steps of clinical validation and regulatory approval.
I for one am very very confident that Avacta will pull this off. Currently its out of their hands for clinical validation and manufacturing.